Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Current Deferred Revenue: 2024-2025

Historic Current Deferred Revenue for Aclaris Therapeutics (ACRS) over the last 1 years, with Sep 2025 value amounting to $3.9 million.

  • Aclaris Therapeutics' Current Deferred Revenue rose 4.25% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 4.25%. This contributed to the annual value of $3.9 million for FY2024, which is N/A change from last year.
  • Per Aclaris Therapeutics' latest filing, its Current Deferred Revenue stood at $3.9 million for Q3 2025, which was up 0.28% from $3.9 million recorded in Q2 2025.
  • Aclaris Therapeutics' Current Deferred Revenue's 5-year high stood at $3.9 million during Q3 2025, with a 5-year trough of $3.8 million in Q3 2024.
  • For the 2-year period, Aclaris Therapeutics' Current Deferred Revenue averaged around $3.9 million, with its median value being $3.9 million (2024).
  • Data for Aclaris Therapeutics' Current Deferred Revenue shows a peak YoY increased of 4.25% (in 2025) over the last 5 years.
  • Aclaris Therapeutics' Current Deferred Revenue (Quarterly) stood at $3.9 million in 2024, then rose by 4.25% to $3.9 million in 2025.
  • Its last three reported values are $3.9 million in Q3 2025, $3.9 million for Q2 2025, and $3.9 million during Q1 2025.